Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
13
3
2021
medline:
20
5
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
We previously reported a higher incidence of non-albumin proteinuria and a small but significant decline in estimated glomerular filtration rate (eGFR) among HIV-negative adults randomized to emtricitabine/tenofovir disoproxil fumarate preexposure prophylaxis (FTC/TDF PrEP) versus placebo. In a nested case--control study among participants randomized to FTC/TDF PrEP, established kidney injury biomarkers measured at 12 months were not significantly different between participants who subsequently experienced one of these kidney endpoints and randomly selected controls who did not.
Identifiants
pubmed: 33710023
doi: 10.1097/QAD.0000000000002865
pii: 00002030-202106010-00018
pmc: PMC8102362
mid: NIHMS1691885
doi:
Substances chimiques
Anti-HIV Agents
0
Biomarkers
0
Tenofovir
99YXE507IL
Emtricitabine
G70B4ETF4S
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1149Subventions
Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK100272
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK112258
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD089843
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women . N Engl J Med 2012; 367:399–410.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men . N Engl J Med 2010; 363:2587–2599.
Dauchy FA, Lawson-Ayayi S, de la Faille R, Bonnet F, Rigothier C, Mehsen N, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy . Kidney Int 2011; 80:302–309.
Mocroft A, Kirk O, Reiss P, De Wit S, Selacek D, Beniowski M, et al. EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients . AIDS 2010; 24:1667–1678.
Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, Shlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection . AIDS 2012; 26:867–875.
Mugwanya KK, Wyatt C, Celum C, Donnell D, Mugo NR, Tappero J, et al. Partners PrEP Study Team. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial . JAMA Intern Med 2015; 175:246–254.
Solomon MM, Lama JR, Glidden DV, Mulligan K, McMahan V, Liu AY, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV preexposure prophylaxis . AIDS 2014; 28:851–859.
Mugwanya KK, Baeten J, Celum C, Donnell D, Nickolas T, Mugo N, et al. Partners PrEP Study Team. Low risk of proximal tubular dysfunction associated with emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis in men and women . J Infect Dis 2016; 214:1050–1057.
Nickolas TL, Schmidt-Ott KM, Canetta P, Forster C, Singer E, Sise M, et al. Diagnostic and prognostic stratification in the emergency department using urinary markers of nephron damage . J Am Coll Cardiol 2012; 59:246–255.